Supplemental Data File 1

Supplemental data file 1. References used in ChromSorter PC

[1-15][16-41][42-74][75-107][108-149][150-192][193-223][224-250]

1. Atkin NB, Baker MC: Chromosome 7q deletions: observations on 13 malignant tumors. Cancer Genet Cytogenet 1993, 67(2):123-125. 2. Atkin NB, Baker MC: Chromosome study of five cancers of the prostate. Hum Genet 1985, 70(4):359-364. 3. Atkin NB, Baker MC: Chromosome 10 deletion in carcinoma of the prostate. N Engl J Med 1985, 312(5):315. 4. Astrom L, Weimarck A, Aldenborg F, Delle U, Hanson C, Verbiene I, Danielsson A, Hammarsten J, Kopf I: S-phase fraction related to prognosis in localised prostate cancer. No specific significance of chromosome 7 gain or deletion of 7q31.1. Int J Cancer 1998, 79(6):553-559. 5. Arps S, Rodewald A, Schmalenberger B, Carl P, Bressel M, Kastendieck H: Cytogenetic survey of 32 cancers of the prostate. Cancer Genet Cytogenet 1993, 66(2):93-99. 6. Alers JC, Rochat J, Krijtenburg PJ, Hop WC, Kranse R, Rosenberg C, Tanke HJ, Schroder FH, van Dekken H: Identification of genetic markers for prostatic cancer progression. Lab Invest 2000, 80(6):931-942. 7. Alers JC, Krijtenburg PJ, Vissers KJ, Bosman FT, van der Kwast TH, van Dekken H: Interphase cytogenetics of prostatic adenocarcinoma and precursor lesions: analysis of 25 radical prostatectomies and 17 adjacent prostatic intraepithelial neoplasias. Genes Chromosomes Cancer 1995, 12(4):241-250. 8. Alers JC, Krijtenburg PJ, Vissers CJ, Bosman FT, van der Kwast TH, van Dekken H: Cytogenetic heterogeneity and histologic tumor growth patterns in prostatic cancer. Cytometry 1995, 21(1):84-94. 9. Alers JC, Krijtenburg PJ, Vis AN, Hoedemaeker RF, Wildhagen MF, Hop WC, van Der Kwast TT, Schroder FH, Tanke HJ, van Dekken H: Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features. Am J Pathol 2001, 158(2):399-406. 10. Alers JC, Krijtenburg PJ, Rosenberg C, Hop WC, Verkerk AM, Schroder FH, van der Kwast TH, Bosman FT, van Dekken H: Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone. Lab Invest 1997, 77(5):437-448. 11. Alers JC, Krijtenburg PJ, Hop WC, Bolle WA, Schroder FH, van der Kwast TH, Bosman FT, van Dekken H: Longitudinal evaluation of cytogenetic aberrations in prostatic cancer: tumours that recur in time display an intermediate genetic status between non-persistent and metastatic tumours. J Pathol 1998, 185(3):273-283. 12. Alcaraz A, Takahashi S, Brown JA, Herath JF, Bergstralh EJ, Larson-Keller JJ, Lieber MM, Jenkins RB: Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res 1994, 54(15):3998-4002. 13. Alcaraz A, Barranco MA, Corral JM, Ribal MJ, Carrio A, Mallofre C, Llopis J, Cetina A, Alvarez-Vijande R: High-grade prostate intraepithelial neoplasia shares cytogenetic alterations with invasive prostate cancer. Prostate 2001, 47(1):29-35. 14. Ahman AK, Jonsson BA, Damber JE, Bergh A, Emanuelsson M, Gronberg H: Low frequency of allelic imbalance at the prostate cancer susceptibility loci HPC1 and 1p36 in Swedish men with hereditary prostate cancer. Genes Chromosomes Cancer 2000, 29(4):292-296. 15. Afonso A, Emmert-Buck MR, Duray PH, Bostwick DG, Linehan WM, Vocke CD: Loss of heterozygosity on chromosome 13 is associated with advanced stage prostate cancer. J Urol 1999, 162(3 Pt 1):922-926. 16. Babu VR, Miles BJ, Cerny JC, Weiss L, Van Dyke DL: Cytogenetic study of four cancers of the prostate. Cancer Genet Cytogenet 1990, 48(1):83-87. 17. Badzioch M, Eeles R, Leblanc G, Foulkes WD, Giles G, Edwards S, Goldgar D, Hopper JL, Bishop DT, Moller P et al: Suggestive evidence for a site specific prostate cancer gene on chromosome 1p36. The CRC/BPG UK Familial Prostate Cancer Study Coordinators and Collaborators. The EU Biomed Collaborators. J Med Genet 2000, 37(12):947-949. 18. Bandyk MG, Zhao L, Troncoso P, Pisters LL, Palmer JL, von Eschenbach AC, Chung LW, Liang JC: Trisomy 7: a potential cytogenetic marker of human prostate cancer progression. Genes Chromosomes Cancer 1994, 9(1):19-27. 19. Baretton GB, Valina C, Vogt T, Schneiderbanger K, Diebold J, Lohrs U: Interphase cytogenetic analysis of prostatic carcinomas by use of nonisotopic in situ hybridization. Cancer Res 1994, 54(16):4472-4480. 20. Barranco MA, Alcaraz A, Corral JM, Sole M, Mallofre C, Llopis J, Rodriguez A, Ribal MJ, Alvarez-Vijande R, Carretero P: Numeric alterations in chromosomes 7 and 8 detected by fluorescent in situ hybridization correlate with high-grade localized prostate cancer. Eur Urol 1998, 34(5):419-425. 21. Beheshti B, Park PC, Sweet JM, Trachtenberg J, Jewett MA, Squire JA: Evidence of chromosomal instability in prostate cancer determined by spectral karyotyping (SKY) and interphase fish analysis. Neoplasia 2001, 3(1):62-69. 22. Bergerheim US, Kunimi K, Collins VP, Ekman P: Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma. Genes Chromosomes Cancer 1991, 3(3):215-220. 23. Bergthorsson JT, Johannesdottir G, Arason A, Benediktsdottir KR, Agnarsson BA, Bailey-Wilson JE, Gillanders E, Smith J, Trent J, Barkardottir RB: Analysis of HPC1, HPCX, and PCaP in Icelandic hereditary prostate cancer. Hum Genet 2000, 107(4):372-375. 24. Bernardino J, Bourgeois CA, Muleris M, Dutrillaux AM, Malfoy B, Dutrillaux B: Characterization of chromosome changes in two human prostatic carcinoma cell lines (PC-3 and DU145) using chromosome painting and comparative genomic hybridization. Cancer Genet Cytogenet 1997, 96(2):123-128. 25. Berry R, Schaid DJ, Smith JR, French AJ, Schroeder JJ, McDonnell SK, Peterson BJ, Wang ZY, Carpten JD, Roberts SG et al: Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer. Am J Hum Genet 2000, 66(2):539- 546. 26. Berry R, Schroeder JJ, French AJ, McDonnell SK, Peterson BJ, Cunningham JM, Thibodeau SN, Schaid DJ: Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet 2000, 67(1):82-91. 27. Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T, Wohr G, Latil A, Millasseau P, Mellah I, Cohen N et al: Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 1998, 62(6):1416-1424. 28. Berube NG, Speevak MD, Chevrette M: Suppression of tumorigenicity of human prostate cancer cells by introduction of human chromosome del(12) (q13). Cancer Res 1994, 54(12):3077-3081. 29. Bishop DT, Kiemeney LA: Family studies and the evidence for genetic susceptibility to prostate cancer. Semin Cancer Biol 1997, 8(1):45-51. 30. Bock CH, Cunningham JM, McDonnell SK, Schaid DJ, Peterson BJ, Pavlic RJ, Schroeder JJ, Klein J, French AJ, Marks A et al: Analysis of the prostate cancer-susceptibility locus HPC20 in 172 families affected by prostate cancer. Am J Hum Genet 2001, 68(3):795-801. 31. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC et al: Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 1993, 53(17):3869-3873. 32. Bova GS, Isaacs WB: Review of allelic loss and gain in prostate cancer. World J Urol 1996, 14(5):338-346. 33. Bova GS, MacGrogan D, Levy A, Pin SS, Bookstein R, Isaacs WB: Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. Genomics 1996, 35(1):46-54. 34. Bratt O, Anderson H, Bak-Jensen E, Baldetorp B, Lundgren R: Metaphase cytogenetics and DNA flow cytometry with analysis of S-phase fraction in prostate cancer: influence on prognosis. Urology 1996, 47(2):218-224. 35. Breitkreuz T, Romanakis K, Lutz S, Seitz G, Bonkhoff H, Unteregger G, Zwergel T, Zang KD, Wullich B: Genotypic characterization of prostatic carcinomas: a combined cytogenetic, flow cytometry, and in situ DNA hybridization study. Cancer Res 1993, 53(17):4035-4040. 36. Brothman AR: Cytogenetic studies in prostate cancer: are we making progress? Cancer Genet Cytogenet 1997, 95(1):116-121. 37. Brothman AR, Patel AM: Characterization of 10 marker chromosomes in a prostatic cancer cell line by in situ hybridization. Cytogenet Cell Genet 1992, 60(1):8-11. 38. Brothman AR, Peehl DM, Patel AM, MacDonald GR, McNeal JE, Ladaga LE, Schellhammer PF: Cytogenetic evaluation of 20 cultured primary prostatic tumors. Cancer Genet Cytogenet 1991, 55(1):79-84. 39. Brothman AR, Steele MR, Williams BJ, Jones E, Odelberg S, Albertsen HM, Jorde LB, Rohr LR, Stephenson RA: Loss of chromosome 17 loci in prostate cancer detected by polymerase chain reaction quantitation of allelic markers. Genes Chromosomes Cancer 1995, 13(4):278-284. 40. Brothman AR, Watson MJ, Zhu XL, Williams BJ, Rohr LR: Evaluation of 20 archival prostate tumor specimens by fluorescence in situ hybridization (FISH). Cancer Genet Cytogenet 1994, 75(1):40-44. 41. Brown JA, Alcaraz A, Takahashi S, Persons DL, Lieber MM, Jenkins RB: Chromosomal aneusomies detected by fluorescent in situ hybridization analysis in clinically localized prostate carcinoma. J Urol 1994, 152(4):1157- 1162. 42. Cabeza-Arvelaiz Y, Sepulveda JL, Lebovitz RM, Thompson TC, Chinault AC: Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22. Oncogene 2001, 20(31):4169-4179. 43. Cancel-Tassin G, Latil A, Valeri A, Guillaume E, Mangin P, Fournier G, Berthon P, Cussenot O: No evidence of linkage to HPC20 on chromosome 20q13 in hereditary prostate cancer. Int J Cancer 2001, 93(3):455-456. 44. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB: Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci U S A 1990, 87(22):8751-8755. 45. Carvalho-Salles AB, Mesquita JC, Tajara EH: Deletion (1)(q12) and double minutes in a metastatic adenocarcinoma of the prostate. Cancer Genet Cytogenet 2000, 116(1):50-53. 46. Chang GT, Steenbeek M, Schippers E, Blok LJ, van Weerden WM, van Alewijk DC, Eussen BH, van Steenbrugge GJ, Brinkmann AO: A novel gene on human chromosome 2p24 is differentially expressed between androgen-dependent and androgen-independent prostate cancer cells. Eur J Cancer 2001, 37(16):2129-2134. 47. Chang GT, Tapsi N, Steenbeek M, Blok LJ, van Weerden WM, van Alewijk DC, Eussen BH, van Steenbrugge GJ, Brinkmann AO: Identification of a gene on human chromosome 8q11 that is differentially expressed during prostate- cancer progression. Int J Cancer 1999, 83(4):506-511. 48. Chekmareva MA, Hollowell CM, Smith RC, Davis EM, LeBeau MM, Rinker- Schaeffer CW: Localization of prostate cancer metastasis-suppressor activity on human chromosome 17. Prostate 1997, 33(4):271-280. 49. Chekmareva MA, Kadkhodaian MM, Hollowell CM, Kim H, Yoshida BA, Luu HH, Stadler WM, Rinker-Schaeffer CW: Chromosome 17-mediated dormancy of AT6.1 prostate cancer micrometastases. Cancer Res 1998, 58(21):4963- 4969. 50. Chen C, Brabham WW, Stultz BG, Frierson HF, Jr., Barrett JC, Sawyers CL, Isaacs JT, Dong JT: Defining a common region of deletion at 13q21 in human cancers. Genes Chromosomes Cancer 2001, 31(4):333-344. 51. Chen TR: Chromosome identity of human prostate cancer cell lines, PC-3 and PPC-1. Cytogenet Cell Genet 1993, 62(2-3):183-184. 52. Cheng L, Song SY, Pretlow TG, Abdul-Karim FW, Kung HJ, Dawson DV, Park WS, Moon YW, Tsai ML, Linehan WM et al: Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst 1998, 90(3):233-237. 53. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH: Genetic alterations in untreated metastases and androgen- independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 1996, 56(13):3091-3102. 54. Cher ML, Ito T, Weidner N, Carroll PR, Jensen RH: Mapping of regions of physical deletion on chromosome 16q in prostate cancer cells by fluorescence in situ hybridization (FISH). J Urol 1995, 153(1):249-254. 55. Cher ML, Lewis PE, Banerjee M, Hurley PM, Sakr W, Grignon DJ, Powell IJ: A similar pattern of chromosomal alterations in prostate cancers from African- Americans and Caucasian Americans. Clin Cancer Res 1998, 4(5):1273-1278. 56. Cher ML, MacGrogan D, Bookstein R, Brown JA, Jenkins RB, Jensen RH: Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes Cancer 1994, 11(3):153-162. 57. Chu LW, Pettaway CA, Liang JC: Genetic abnormalities specifically associated with varying metastatic potential of prostate cancer cell lines as detected by comparative genomic hybridization. Cancer Genet Cytogenet 2001, 127(2):161-167. 58. Cooney KA, McCarthy JD, Lange E, Huang L, Miesfeldt S, Montie JE, Oesterling JE, Sandler HM, Lange K: Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst 1997, 89(13):955- 959. 59. Cooney KA, Wetzel JC, Consolino CM, Wojno KJ: Identification and characterization of proximal 6q deletions in prostate cancer. Cancer Res 1996, 56(18):4150-4153. 60. Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singleton TP, Wojno KJ: Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res 1996, 56(5):1142-1145. 61. Corral Molina JM, Alcaraz Asensio A, Barranco Sanz MA, Mallofre Gomez C, Ribal Caparros MJ, Cetina Herrando A, Beardo Villar P, Muntane Casasus J, Llopis Manzaneda J, Carretero Gonzalez P: [High incidence of chromosome 8 monosomy and chromosome 7 trisomy in prostatic primary tumor and its related lymphatic metastasis. Preliminary results]. Actas Urol Esp 1998, 22(10):811-817. 62. Crundwell MC, Arkell DG, Gearty J, Phillips SM: Genetic alterations in incidentally diagnosed, transitional zone prostate cancer: a seven year follow- up. J Urol 1997, 158(4):1568-1575. 63. Crundwell MC, Chughtai S, Knowles M, Takle L, Luscombe M, Neoptolemos JP, Morton DG, Phillips SM: Allelic loss on chromosomes 8p, 22q and 18q (DCC) in human prostate cancer. Int J Cancer 1996, 69(4):295-300. 64. Cui J, Deubler DA, Rohr LR, Zhu XL, Maxwell TM, Changus JE, Brothman AR: Chromosome 7 abnormalities in prostate cancer detected by dual-color fluorescence in situ hybridization. Cancer Genet Cytogenet 1998, 107(1):51-60. 65. Cunningham JM, Shan A, Wick MJ, McDonnell SK, Schaid DJ, Tester DJ, Qian J, Takahashi S, Jenkins RB, Bostwick DG et al: Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res 1996, 56(19):4475-4482. 66. Dahiya R, Lee C, McCarville J, Hu W, Kaur G, Deng G: High frequency of genetic instability of microsatellites in human prostatic adenocarcinoma. Int J Cancer 1997, 72(5):762-767. 67. Dahiya R, McCarville J, Hu W, Lee C, Chui RM, Kaur G, Deng G: Chromosome 3p24-26 and 3p22-12 loss in human prostatic adenocarcinoma. Int J Cancer 1997, 71(1):20-25. 68. Dahiya R, McCarville J, Lee C, Hu W, Kaur G, Carroll P, Deng G: Deletion of chromosome 11p15, p12, q22, q23-24 loci in human prostate cancer. Int J Cancer 1997, 72(2):283-288. 69. Dahiya R, Yoon WH, Boyle B, Schoenberg S, Yen TS, Narayan P: Biochemical, cytogenetic, and morphological characteristics of human primary and metastatic prostate cancer cell lines. Biochem Int 1992, 27(4):567-577. 70. Dai Q, Deubler DA, Maxwell TM, Zhu XL, Cui J, Rohr LR, Stephenson RA, Brothman AR: A common deletion at chromosomal region 17q21 in sporadic prostate tumors distal to BRCA1. Genomics 2001, 71(3):324-329. 71. Debruyne FM, Collins VP, van Dekken H, Jenkins RB, Klocker H, Schalken JA, Sesterhenn IA: Cytogenetics of prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. Scand J Urol Nephrol Suppl 1994, 162:65-71. 72. Degeorges A, Hoffschir F, Cussenot O, Gauville C, Le Duc A, Dutrillaux B, Calvo F: Recurrent cytogenetic alterations of prostate carcinoma and amplification of c-myc or epidermal growth factor receptor in subclones of immortalized PNT1 human prostate epithelial cell line. Int J Cancer 1995, 62(6):724-731. 73. Deubler DA, Williams BJ, Zhu XL, Steele MR, Rohr LR, Jensen JC, Stephenson RA, Changus JE, Miller GJ, Becich MJ et al: Allelic loss detected on chromosomes 8, 10, and 17 by fluorescence in situ hybridization using single- copy P1 probes on isolated nuclei from paraffin-embedded prostate tumors. Am J Pathol 1997, 150(3):841-850. 74. Dong JT, Chen C, Stultz BG, Isaacs JT, Frierson HF, Jr.: Deletion at 13q21 is associated with aggressive prostate cancers. Cancer Res 2000, 60(14):3880- 3883. 75. Eeles RA, Durocher F, Edwards S, Teare D, Badzioch M, Hamoudi R, Gill S, Biggs P, Dearnaley D, Ardern-Jones A et al: Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. Am J Hum Genet 1998, 62(3):653-658. 76. El Gedaily A, Bubendorf L, Willi N, Fu W, Richter J, Moch H, Mihatsch MJ, Sauter G, Gasser TC: Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization. Prostate 2001, 46(3):184-190. 77. Elo JP, Harkonen P, Kyllonen AP, Lukkarinen O, Poutanen M, Vihko R, Vihko P: Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer. Cancer Res 1997, 57(16):3356-3359. 78. Elo JP, Harkonen P, Kyllonen AP, Lukkarinen O, Vihko P: Three independently deleted regions at chromosome arm 16q in human prostate cancer: allelic loss at 16q24.1-q24.2 is associated with aggressive behaviour of the disease, recurrent growth, poor differentiation of the tumour and poor prognosis for the patient. Br J Cancer 1999, 79(1):156-160. 79. Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence CD, Zhuang Z, Bostwick DG, Liotta LA, Linehan WM: Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 1995, 55(14):2959-2962. 80. Erbersdobler A, Bardenhagen P, Henke RP: Numerical chromosomal anomalies in latent adenocarcinomas of the prostate. Prostate 1999, 38(2):92-99. 81. Erbersdobler A, Gurses N, Henke RP: Numerical chromosomal changes in high-grade prostatic intraepithelial neoplasia (PIN) and concomitant invasive carcinoma. Pathol Res Pract 1996, 192(5):418-427. 82. Erbersdobler A, Hammerer P, Huland H, Henke RP: Numerical chromosomal aberrations in transition-zone carcinomas of the prostate. J Urol 1997, 158(4):1594-1598. 83. Ewing CM, Ru N, Morton RA, Robinson JC, Wheelock MJ, Johnson KR, Barrett JC, Isaacs WB: Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of alpha-catenin and restoration of E- cadherin function. Cancer Res 1995, 55(21):4813-4817. 84. Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM: Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 1998, 16(13):1743-1748. 85. Fiedler U, Ehlers W, Meye A, Fussel S, Faller G, Schmidt U, Wirth MP: LOH analyses in the region of the putative tumour suppressor gene C13 on chromosome 13q13. Anticancer Res 2001, 21(4A):2341-2350. 86. Ford S, Gray IC, Spurr NK: Rearrangement of the long arm of chromosome 10 in the prostate adenocarcinoma cell line LNCaP. Cancer Genet Cytogenet 1998, 102(1):6-11. 87. Fu W, Bubendorf L, Willi N, Moch H, Mihatsch MJ, Sauter G, Gasser TC: Genetic changes in clinically organ-confined prostate cancer by comparative genomic hybridization. Urology 2000, 56(5):880-885. 88. Fukuhara H, Maruyama T, Nomura S, Oshimura M, Kitamura T, Sekiya T, Murakami Y: Functional evidence for the presence of tumor suppressor gene on chromosome 10p15 in human prostate cancers. Oncogene 2001, 20(3):314- 319. 89. Gao AC, Lou W, Ichikawa T, Denmeade SR, Barrett JC, Isaacs JT: Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1-13.2. Prostate 1999, 38(1):46-54. 90. Gao X, Zacharek A, Grignon DJ, Sakr W, Powell IJ, Porter AT, Honn KV: Localization of potential tumor suppressor loci to a < 2 Mb region on chromosome 17q in human prostate cancer. Oncogene 1995, 11(7):1241-1247. 91. Gibas Z, Pontes JE, Sandberg AA: Chromosome rearrangements in a metastatic adenocarcinoma of the prostate. Cancer Genet Cytogenet 1985, 16(4):301-304. 92. Gibbs M, Chakrabarti L, Stanford JL, Goode EL, Kolb S, Schuster EF, Buckley VA, Shook M, Hood L, Jarvik GP et al: Analysis of chromosome 1q42.2-43 in 152 families with high risk of prostate cancer. Am J Hum Genet 1999, 64(4):1087-1095. 93. Gibbs M, Stanford JL, Jarvik GP, Janer M, Badzioch M, Peters MA, Goode EL, Kolb S, Chakrabarti L, Shook M et al: A genomic scan of families with prostate cancer identifies multiple regions of interest. Am J Hum Genet 2000, 67(1):100-109. 94. Gibbs M, Stanford JL, McIndoe RA, Jarvik GP, Kolb S, Goode EL, Chakrabarti L, Schuster EF, Buckley VA, Miller EL et al: Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet 1999, 64(3):776-787. 95. Goddard KA, Witte JS, Suarez BK, Catalona WJ, Olson JM: Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4. Am J Hum Genet 2001, 68(5):1197-1206. 96. Godfrey TE, Cher ML, Chhabra V, Jensen RH: Allelic imbalance mapping of chromosome 16 shows two regions of common deletion in prostate adenocarcinoma. Cancer Genet Cytogenet 1997, 98(1):36-42. 97. Goodarzi G, Mashimo T, Watabe M, Cuthbert AP, Newbold RF, Pai SK, Hirota S, Hosobe S, Miura K, Bandyopadhyay S et al: Identification of tumor metastasis suppressor region on the short arm of human chromosome 20. Genes Chromosomes Cancer 2001, 32(1):33-42. 98. Goode EL, Stanford JL, Chakrabarti L, Gibbs M, Kolb S, McIndoe RA, Buckley VA, Schuster EF, Neal CL, Miller EL et al: Linkage analysis of 150 high-risk prostate cancer families at 1q24-25. Genet Epidemiol 2000, 18(3):251-275. 99. Gray IC, Phillips SM, Lee SJ, Neoptolemos JP, Weissenbach J, Spurr NK: Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res 1995, 55(21):4800-4803. 100. Gronberg H, Isaacs SD, Smith JR, Carpten JD, Bova GS, Freije D, Xu J, Meyers DA, Collins FS, Trent JM et al: Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. Jama 1997, 278(15):1251-1255. 101. Gronberg H, Smith J, Emanuelsson M, Jonsson BA, Bergh A, Carpten J, Isaacs W, Xu J, Meyers D, Trent J et al: In Swedish families with hereditary prostate cancer, linkage to the HPC1 locus on chromosome 1q24-25 is restricted to families with early- onset prostate cancer. Am J Hum Genet 1999, 65(1):134- 140. 102. Gronberg H, Xu J, Smith JR, Carpten JD, Isaacs SD, Freije D, Bova GS, Danber JE, Bergh A, Walsh PC et al: Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1. Cancer Res 1997, 57(21):4707-4709. 103. Haggman MJ, Wojno KJ, Pearsall CP, Macoska JA: Allelic loss of 8p sequences in prostatic intraepithelial neoplasia and carcinoma. Urology 1997, 50(4):643- 647. 104. Heidenreich B, Heidenreich A, Sesterhenn A, Srivastava S, Moul JW, Sesterhenn IA: Aneuploidy of chromosome 9 and the tumor suppressor genes p16(INK4) and p15(INK4B) detected by in situ hybridization in locally advanced prostate cancer. Eur Urol 2000, 38(4):475-482. 105. Henke RP, Kruger E, Ayhan N, Hubner D, Hammerer P: Frequency and distribution of numerical chromosomal aberrations in prostatic cancer. Hum Pathol 1994, 25(5):476-484. 106. Hsieh CL, Oakley-Girvan I, Gallagher RP, Wu AH, Kolonel LN, Teh CZ, Halpern J, West DW, Paffenbarger RS, Jr., Whittemore AS: Re: prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst 1997, 89(24):1893-1894. 107. Hyytinen ER, Frierson HF, Jr., Boyd JC, Chung LW, Dong JT: Three distinct regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer. Genes Chromosomes Cancer 1999, 25(2):108-114. 108. Ichikawa T, Hosoki S, Suzuki H, Akakura K, Igarashi T, Furuya Y, Oshimura M, Rinker-Schaeffer CW, Nihei N, Barrett JC et al: Mapping of metastasis suppressor genes for prostate cancer by microcell- mediated chromosome transfer. Asian J Androl 2000, 2(3):167-171. 109. Ichikawa T, Nihei N, Suzuki H, Oshimura M, Emi M, Nakamura Y, Hayata I, Isaacs JT, Shimazaki J: Suppression of metastasis of rat prostatic cancer by introducing human chromosome 8. Cancer Res 1994, 54(9):2299-2302. 110. Isaacs JT, Hukku B: Nonrandom involvement of chromosome 4 in the progression of rat prostatic cancer. Prostate 1988, 13(2):165-188. 111. Isaacs WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM: Genetic alterations in prostate cancer. Cold Spring Harb Symp Quant Biol 1994, 59:653-659. 112. Ittmann M: Allelic loss on chromosome 10 in prostate adenocarcinoma. Cancer Res 1996, 56(9):2143-2147. 113. Ittmann MM: Loss of heterozygosity on chromosomes 10 and 17 in clinically localized prostate carcinoma. Prostate 1996, 28(5):275-281. 114. Jackson-Cook C, Bae V, Edelman W, Brothman A, Ware J: Cytogenetic characterization of the human prostate cancer cell line P69SV40T and its novel tumorigenic sublines M2182 and M15. Cancer Genet Cytogenet 1996, 87(1):14-23. 115. Jarvik GP, Stanford JL, Goode EL, McIndoe R, Kolb S, Gibbs M, Hood L, Ostrander EA: Confirmation of prostate cancer susceptibility genes using high-risk families. J Natl Cancer Inst Monogr 1999, 26:81-87. 116. Jenkins R, Takahashi S, DeLacey K, Bergstralh E, Lieber M: Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer. Genes Chromosomes Cancer 1998, 21(2):131- 143. 117. Jenkins RB, Qian J, Lee HK, Huang H, Hirasawa K, Bostwick DG, Proffitt J, Wilber K, Lieber MM, Liu W et al: A molecular cytogenetic analysis of 7q31 in prostate cancer. Cancer Res 1998, 58(4):759-766. 118. Jones E, Zhu XL, Rohr LR, Stephenson RA, Brothman AR: Aneusomy of chromosomes 7 and 17 detected by FISH in prostate cancer and the effects of selection in vitro. Genes Chromosomes Cancer 1994, 11(3):163-170. 119. Joos S, Bergerheim US, Pan Y, Matsuyama H, Bentz M, du Manoir S, Lichter P: Mapping of chromosomal gains and losses in prostate cancer by comparative genomic hybridization. Genes Chromosomes Cancer 1995, 14(4):267-276. 120. Jordan JJ, Hanlon AL, Al-Saleem TI, Greenberg RE, Tricoli JV: Loss of the short arm of the Y chromosome in human prostate carcinoma. Cancer Genet Cytogenet 2001, 124(2):122-126. 121. Kagan J, Stein J, Babaian RJ, Joe YS, Pisters LL, Glassman AB, von Eschenbach AC, Troncoso P: Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. Oncogene 1995, 11(10):2121-2126. 122. Kalapurakal JA, Jacob AN, Kim PY, Najjar DD, Hsieh YC, Ginsberg P, Daskal I, Asbell SO, Kandpal RP: Racial differences in prostate cancer related to loss of heterozygosity on chromosome 8p12-23. Int J Radiat Oncol Biol Phys 1999, 45(4):835-840. 123. Karashima T, Taguchi T, Yoshikawa C, Kamada M, Kasahara K, Yuri K, Shuin T: Numerical chromosomal changes in metastatic prostate cancer following anti-androgen therapy: fluorescence in situ hybridization analysis of 5 Japanese cases. Cancer Genet Cytogenet 2000, 120(2):148-154. 124. Kasahara K, Taguchi T, Inoue K, Shuin T, Kariya S, Yoshida S, Furihata M: Early reduction in the aneuploidy at chromosomes 7 and 8 are significantly corrrelated with clinical effect in high-dose rate brachytherapy with external beam radiotherapy in localized prostate cancer. Int J Mol Med 2001, 8(6):667- 673. 125. Kasahara K, Taguchi T, Yamasaki I, Karashima T, Kamada M, Yuri K, Shuin T: Fluorescence in situ hybridization to assess transitional changes of aneuploidy for chromosomes 7, 8, 10, 12, 16, X and Y in metastatic prostate cancer following anti-androgen therapy. Int J Oncol 2001, 19(3):543-549. 126. Kibel AS, Freije D, Isaacs WB, Bova GS: Deletion mapping at 12p12-13 in metastatic prostate cancer. Genes Chromosomes Cancer 1999, 25(3):270-276. 127. Kibel AS, Schutte M, Kern SE, Isaacs WB, Bova GS: Identification of 12p as a region of frequent deletion in advanced prostate cancer. Cancer Res 1998, 58(24):5652-5655. 128. Koivisto PA: Molecular cytogenetics of prostate cancer. Crit Rev Oncog 1996, 7(3-4):143-150. 129. Komiya A, Suzuki H, Ueda T, Yatani R, Emi M, Ito H, Shimazaki J: Allelic losses at loci on chromosome 10 are associated with metastasis and progression of human prostate cancer. Genes Chromosomes Cancer 1996, 17(4):245-253. 130. Konig JJ, Teubel W, Romijn JC, Schroder FH, Hagemeijer A: Gain and loss of chromosomes 1, 7, 8, 10, 18, and Y in 46 prostate cancers. Hum Pathol 1996, 27(7):720-727. 131. Konig JJ, Teubel W, van Dongen JW, Romijn JC, Hagemeijer A, Schroder FH: Loss and gain of chromosomes 1, 18, and Y in prostate cancer. Prostate 1994, 25(6):281-291. 132. Konig JJ, Teubel W, van Steenbrugge GJ, Romijn JC, Hagemeijer A: Characterization of chromosome 8 aberrations in the prostate cancer cell line LNCaP-FGC and sublines. Urol Res 1999, 27(1):3-8. 133. Kuramochi H, Ichikawa T, Nihei N, Kawana Y, Suzuki H, Schalken JA, Takeichi M, Nagafuchi A, Ito H, Shimazaki J: Suppression of invasive ability of highly metastatic rat prostate cancer by introduction of human chromosome 8. Prostate 1997, 31(1):14-20. 134. Lacombe L, Orlow I, Reuter VE, Fair WR, Dalbagni G, Zhang ZF, Cordon-Cardo C: Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer. Int J Cancer 1996, 69(2):110-113. 135. Lange EM, Chen H, Brierley K, Livermore H, Wojno KJ, Langefeld CD, Lange K, Cooney KA: The polymorphic exon 1 androgen receptor CAG repeat in men with a potential inherited predisposition to prostate cancer. Cancer Epidemiol Biomarkers Prev 2000, 9(4):439-442. 136. Lange EM, Chen H, Brierley K, Perrone EE, Bock CH, Gillanders E, Ray ME, Cooney KA: Linkage analysis of 153 prostate cancer families over a 30-cM region containing the putative susceptibility locus HPCX. Clin Cancer Res 1999, 5(12):4013-4020. 137. Latil A, Baron JC, Cussenot O, Fournier G, Soussi T, Boccon-Gibod L, Le Duc A, Rouesse J, Lidereau R: Genetic alterations in localized prostate cancer: identification of a common region of deletion on chromosome arm 18q. Genes Chromosomes Cancer 1994, 11(2):119-125. 138. Latil A, Bieche I, Pesche S, Volant A, Valeri A, Fournier G, Cussenot O, Lidereau R: Loss of heterozygosity at chromosome arm 13q and RB1 status in human prostate cancer. Hum Pathol 1999, 30(7):809-815. 139. Latil A, Cussenot O, Fournier G, Baron JC, Lidereau R: Loss of heterozygosity at 7q31 is a frequent and early event in prostate cancer. Clin Cancer Res 1995, 1(11):1385-1389. 140. Latil A, Cussenot O, Fournier G, Driouch K, Lidereau R: Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions. Cancer Res 1997, 57(6):1058-1062. 141. Latil A, Cussenot O, Fournier G, Lidereau R: Infrequent allelic imbalance at the major susceptibility HPC1 locus in sporadic prostate tumours. Int J Cancer 1997, 71(6):1118. 142. Latil A, Fournier G, Cussenot O, Lidereau R: Differential chromosome allelic imbalance in the progression of human prostate cancer. J Urol 1996, 156(6):2079-2083. 143. Latil A, Guerard M, Berthon P, Cussenot O: 12p12-13 deletion in prostate tumors and quantitative expression of CDKN1B and ETV6 candidate genes. Genes Chromosomes Cancer 2001, 31(2):199-200. 144. Li C, Berx G, Larsson C, Auer G, Aspenblad U, Pan Y, Sundelin B, Ekman P, Nordenskjold M, van Roy F et al: Distinct deleted regions on chromosome segment 16q23-24 associated with metastases in prostate cancer. Genes Chromosomes Cancer 1999, 24(3):175-182. 145. Li C, Larsson C, Futreal A, Lancaster J, Phelan C, Aspenblad U, Sundelin B, Liu Y, Ekman P, Auer G et al: Identification of two distinct deleted regions on chromosome 13 in prostate cancer. Oncogene 1998, 16(4):481-487. 146. Lundgren R: Cytogenetic studies of prostatic cancer. Scand J Urol Nephrol Suppl 1991, 136:1-35. 147. Lundgren R, Kristoffersson U, Heim S, Mandahl N, Mitelman F: Multiple structural chromosome rearrangements, including del(7q) and del(10q), in an adenocarcinoma of the prostate. Cancer Genet Cytogenet 1988, 35(1):103- 108. 148. Lundgren R, Mandahl N, Heim S, Limon J, Henrikson H, Mitelman F: Cytogenetic analysis of 57 primary prostatic adenocarcinomas. Genes Chromosomes Cancer 1992, 4(1):16-24. 149. Lutchman M, Pack S, Kim AC, Azim A, Emmert-Buck M, van Huffel C, Zhuang Z, Chishti AH: Loss of heterozygosity on 8p in prostate cancer implicates a role for dematin in tumor progression. Cancer Genet Cytogenet 1999, 115(1):65-69. 150. MacGrogan D, Levy A, Bostwick D, Wagner M, Wells D, Bookstein R: Loss of chromosome arm 8p loci in prostate cancer: mapping by quantitative allelic imbalance. Genes Chromosomes Cancer 1994, 10(3):151-159. 151. Macintosh CA, Stower M, Reid N, Maitland NJ: Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res 1998, 58(1):23-28. 152. Macoska JA, Beheshti B, Rhim JS, Hukku B, Lehr J, Pienta KJ, Squire JA: Genetic characterization of immortalized human prostate epithelial cell cultures. Evidence for structural rearrangements of chromosome 8 and i(8q) chromosome formation in primary tumor-derived cells. Cancer Genet Cytogenet 2000, 120(1):50-57. 153. Macoska JA, Micale MA, Sakr WA, Benson PD, Wolman SR: Extensive genetic alterations in prostate cancer revealed by dual PCR and FISH analysis. Genes Chromosomes Cancer 1993, 8(2):88-97. 154. Macoska JA, Powell IJ, Sakr W, Lane MA: Loss of the 17p chromosomal region in a metastatic carcinoma of the prostate. J Urol 1992, 147(4):1142- 1146. 155. Macoska JA, Trybus TM, Benson PD, Sakr WA, Grignon DJ, Wojno KD, Pietruk T, Powell IJ: Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer. Cancer Res 1995, 55(22):5390-5395. 156. Macoska JA, Trybus TM, Sakr WA, Wolf MC, Benson PD, Powell IJ, Pontes JE: Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer. Cancer Res 1994, 54(14):3824-3830. 157. Mashimo T, Watabe M, Cuthbert AP, Newbold RF, Rinker-Schaeffer CW, Helfer E, Watabe K: Human chromosome 16 suppresses metastasis but not tumorigenesis in rat prostatic tumor cells. Cancer Res 1998, 58(20):4572-4576. 158. Matsuura H, Shiraishi T, Yatani R, Kawamura J: Interphase cytogenetics of prostate cancer: fluorescence in situ hybridisation (FISH) analysis of Japanese cases. Br J Cancer 1996, 74(11):1699-1704. 159. Matsuyama H, Pan Y, Oba K, Yoshihiro S, Matsuda K, Hagarth L, Kudren D, Naito K, Bergerheim US, Ekman P: Deletions on chromosome 8p22 may predict disease progression as well as pathological staging in prostate cancer. Clin Cancer Res 2001, 7(10):3139-3143. 160. Matsuyama H, Pan Y, Skoog L, Tribukait B, Naito K, Ekman P, Lichter P, Bergerheim US: Deletion mapping of chromosome 8p in prostate cancer by fluorescence in situ hybridization. Oncogene 1994, 9(10):3071-3076. 161. Matturri L, Biondo B, Cazzullo A, Montanari E, Radice F, Timossi R, Turconi P, Lavezzi AM: Detection of trisomy 7 with fluorescence in situ hybridization and its correlation with DNA content and proliferating cell nuclear antigen- positivity in prostate cancer. Am J Clin Oncol 1998, 21(3):253-257. 162. McIndoe RA, Stanford JL, Gibbs M, Jarvik GP, Brandzel S, Neal CL, Li S, Gammack JT, Gay AA, Goode EL et al: Linkage analysis of 49 high-risk families does not support a common familial prostate cancer-susceptibility gene at 1q24-25. Am J Hum Genet 1997, 61(2):347-353. 163. Melamed J, Einhorn JM, Ittmann MM: Allelic loss on chromosome 13q in human prostate carcinoma. Clin Cancer Res 1997, 3(10):1867-1872. 164. Mesker WE, Alers JC, Sloos WC, Vrolijk H, Raap AK, Dekken HV, Tanke HJ: Automated assessment of numerical chromosomal aberrations in paraffin embedded prostate tumor cells stained by in situ hybridization. Cytometry 1996, 26(4):298-304. 165. Micale MA, Mohamed A, Sakr W, Powell IJ, Wolman SR: Cytogenetics of primary prostatic adenocarcinoma. Clonality and chromosome instability. Cancer Genet Cytogenet 1992, 61(2):165-173. 166. Milasin J, Micic S: Double minute chromosomes in an invasive adenocarcinoma of the prostate. Cancer Genet Cytogenet 1994, 72(2):157-159. 167. Molenaar WM, Stoepker ME, de Ruiter AJ, Hoekstra HJ, van den Berg E: Cytogenetic support for primary prostatic cancer in a patient presenting with a soft tissue mass in the leg. Cancer Genet Cytogenet 1996, 86(2):147-149. 168. Monroe KR, Yu MC, Kolonel LN, Coetzee GA, Wilkens LR, Ross RK, Henderson BE: Evidence of an X-linked or recessive genetic component to prostate cancer risk. Nat Med 1995, 1(8):827-829. 169. Morton RA, Jr., Watkins JJ, Bova GS, Wales MM, Baylin SB, Isaacs WB: Hypermethylation of chromosome 17P locus D17S5 in human prostate tissue. J Urol 1996, 156(2 Pt 1):512-516. 170. Murakami YS, Albertsen H, Brothman AR, Leach RJ, White RL: Suppression of the malignant phenotype of human prostate cancer cell line PPC-1 by introduction of normal fragments of human chromosome 10. Cancer Res 1996, 56(9):2157-2160. 171. Murakami YS, Brothman AR, Leach RJ, White RL: Suppression of malignant phenotype in a human prostate cancer cell line by fragments of normal chromosomal region 17q. Cancer Res 1995, 55(15):3389-3394. 172. Neuhausen SL, Farnham JM, Kort E, Tavtigian SV, Skolnick MH, Cannon- Albright LA: Prostate cancer susceptibility locus HPC1 in Utah high-risk pedigrees. Hum Mol Genet 1999, 8(13):2437-2442. 173. Nihei N, Ichikawa T, Kawana Y, Kuramochi H, Kugo H, Oshimura M, Killary AM, Rinker-Schaeffer CW, Barrett JC, Isaacs JT et al: Localization of metastasis suppressor gene(s) for rat prostatic cancer to the long arm of human chromosome 10. Genes Chromosomes Cancer 1995, 14(2):112-119. 174. Nihei N, Ichikawa T, Kawana Y, Kuramochi H, Kugoh H, Oshimura M, Hayata I, Shimazaki J, Ito H: Mapping of metastasis suppressor gene(s) for rat prostate cancer on the short arm of human chromosome 8 by irradiated microcell- mediated chromosome transfer. Genes Chromosomes Cancer 1996, 17(4):260- 268. 175. Nihei N, Ohta S, Kuramochi H, Kugoh H, Oshimura M, Barrett JC, Isaacs JT, Igarashi T, Ito H, Masai M et al: Metastasis suppressor gene(s) for rat prostate cancer on the long arm of human chromosome 7. Genes Chromosomes Cancer 1999, 24(1):1-8. 176. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T: Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 1998, 153(1):141-148. 177. Oba K, Matsuyama H, Yoshihiro S, Kishi F, Takahashi M, Tsukamoto M, Kinjo M, Sagiyama K, Naito K: Two putative tumor suppressor genes on chromosome arm 8p may play different roles in prostate cancer. Cancer Genet Cytogenet 2001, 124(1):20-26. 178. Osman I, Scher H, Dalbagni G, Reuter V, Zhang ZF, Cordon-Cardo C: Chromosome 16 in primary prostate cancer: a microsatellite analysis. Int J Cancer 1997, 71(4):580-584. 179. Ozen M, Hopwood VL, Balbay MD, Johnston DA, Babaian RJ, Logothetis CJ, von Eschenbach AC, Pathak S: Correlation of non-random chromosomal aberrations in lymphocytes of prostate cancer patients with specific clinical parameters. Int J Oncol 2000, 17(1):113-117. 180. Ozen M, Navone NM, Multani AS, Troncoso P, Logothetis CJ, Chung LW, von Eschenbach AC, Pathak S: Structural alterations of chromosome 5 in twelve human prostate cancer cell lines. Cancer Genet Cytogenet 1998, 106(2):105- 109. 181. Padalecki SS, Johnson-Pais TL, Killary AM, Leach RJ: Chromosome 18 suppresses the tumorigenicity of prostate cancer cells. Genes Chromosomes Cancer 2001, 30(3):221-229. 182. Padalecki SS, Troyer DA, Hansen MF, Saric T, Schneider BG, O'Connell P, Leach RJ: Identification of two distinct regions of allelic imbalance on chromosome 18Q in metastatic prostate cancer. Int J Cancer 2000, 85(5):654- 658. 183. Paige AJ, Taylor KJ, Stewart A, Sgouros JG, Gabra H, Sellar GC, Smyth JF, Porteous DJ, Watson JE: A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D. Cancer Res 2000, 60(6):1690-1697. 184. Paiss T, Bochum S, Herkommer K, Maier C, Roesch K, Taweemonkonsap T, Haeussler J, Hautmann RE, Vogel W: Hereditary prostate cancer in germany. Eur Urol 2001, 39 Suppl 4:12-18. 185. Pan Y, Lui WO, Nupponen N, Larsson C, Isola J, Visakorpi T, Bergerheim US, Kytola S: 5q11, 8p11, and 10q22 are recurrent chromosomal breakpoints in prostate cancer cell lines. Genes Chromosomes Cancer 2001, 30(2):187-195. 186. Paris PL, Witte JS, Kupelian PA, Levin H, Klein EA, Catalona WJ, Casey G: Identification and fine mapping of a region showing a high frequency of allelic imbalance on chromosome 16q23.2 that corresponds to a prostate cancer susceptibility locus. Cancer Res 2000, 60(13):3645-3649. 187. Perinchery G, Bukurov N, Nakajima K, Chang J, Hooda M, Oh BR, Dahiya R: Loss of two new loci on chromosome 8 (8p23 and 8q12-13) in human prostate cancer. Int J Oncol 1999, 14(3):495-500. 188. Perinchery G, Bukurov N, Nakajima K, Chang J, Li LC, Dahiya R: High frequency of deletion on chromosome 9p21 may harbor several tumor- suppressor genes in human prostate cancer. Int J Cancer 1999, 83(5):610-614. 189. Perinchery G, Sasaki M, Angan A, Kumar V, Carroll P, Dahiya R: Deletion of Y- chromosome specific genes in human prostate cancer. J Urol 2000, 163(4):1339-1342. 190. Peters MA, Jarvik GP, Janer M, Chakrabarti L, Kolb S, Goode EL, Gibbs M, DuBois CC, Schuster EF, Hood L et al: Genetic linkage analysis of prostate cancer families to Xq27-28. Hum Hered 2001, 51(1-2):107-113. 191. Powell IJ, Meyskens FL, Jr.: African American men and hereditary/familial prostate cancer: Intermediate-risk populations for chemoprevention trials. Urology 2001, 57(4 Suppl 1):178-181. 192. Prasad MA, Trybus TM, Wojno KJ, Macoska JA: Homozygous and frequent deletion of proximal 8p sequences in human prostate cancers: identification of a potential tumor suppressor gene site. Genes Chromosomes Cancer 1998, 23(3):255-262. 193. Qi H, Dal Cin P, Van de Voorde W, Elgamal AA, Van Poppel H, Baert L, Van Den Berghe H: del(1)(q12) in adenocarcinomas of the prostate. Cancer Genet Cytogenet 1996, 87(1):79-81. 194. Rinker-Schaeffer CW, Hawkins AL, Ru N, Dong J, Stoica G, Griffin CA, Ichikawa T, Barrett JC, Isaacs JT: Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11. Cancer Res 1994, 54(23):6249-6256. 195. Rohrbach H, Haas CJ, Baretton GB, Hirschmann A, Diebold J, Behrendt RP, Lohrs U: Microsatellite instability and loss of heterozygosity in prostatic carcinomas: comparison of primary tumors, and of corresponding recurrences after androgen-deprivation therapy and lymph-node metastases. Prostate 1999, 40(1):20-27. 196. Rokman A, Koivisto PA, Matikainen MP, Kuukasjarvi T, Poutiainen M, Helin HJ, Karhu R, Kallioniemi OP, Schleutker J: Genetic changes in familial prostate cancer by comparative genomic hybridization. Prostate 2001, 46(3):233-239. 197. Rubin MA, Gerstein A, Reid K, Bostwick DG, Cheng L, Parsons R, Papadopoulos N: 10q23.3 loss of heterozygosity is higher in lymph node- positive (pT2- 3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer. Hum Pathol 2000, 31(4):504-508. 198. Sandberg AA: Chromosomal abnormalities and related events in prostate cancer. Hum Pathol 1992, 23(4):368-380. 199. Sandberg AA: Cytogenetic and molecular genetic aspects of human prostate cancer: primary and metastatic. Adv Exp Med Biol 1992, 324:45-75. 200. Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ, Jenkins RB: Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst 1999, 91(18):1574-1580. 201. Sattler HP, Lensch R, Rohde V, Zimmer E, Meese E, Bonkhoff H, Retz M, Zwergel T, Bex A, Stoeckle M et al: Novel amplification unit at chromosome 3q25-q27 in human prostate cancer. Prostate 2000, 45(3):207-215. 202. Schaid DJ, McDonnell SK, Thibodeau SN: Regression models for linkage heterogeneity applied to familial prostate cancer. Am J Hum Genet 2001, 68(5):1189-1196. 203. Schleutker J, Matikainen M, Smith J, Koivisto P, Baffoe-Bonnie A, Kainu T, Gillanders E, Sankila R, Pukkala E, Carpten J et al: A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: frequent HPCX linkage in families with late-onset disease. Clin Cancer Res 2000, 6(12):4810- 4815. 204. Singh R: No evidence of linkage to chromosome 1q42.2-43 in 131 prostate cancer families from the ACTANE consortium. Anglo, Canada, Texas, Australia, Norway, EU Biomed. Br J Cancer 2000, 83(12):1654-1658. 205. Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P et al: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996, 274(5291):1371-1374. 206. Strup SE, Pozzatti RO, Florence CD, Emmert-Buck MR, Duray PH, Liotta LA, Bostwick DG, Linehan WM, Vocke CD: Chromosome 16 allelic loss analysis of a large set of microdissected prostate carcinomas. J Urol 1999, 162(2):590- 594. 207. Suarez BK, Gerhard DS, Lin J, Haberer B, Nguyen L, Kesterson NK, Catalona WJ: Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls. Cancer Res 2001, 61(13):4982- 4984. 208. Suarez BK, Lin J, Burmester JK, Broman KW, Weber JL, Banerjee TK, Goddard KA, Witte JS, Elston RC, Catalona WJ: A genome screen of multiplex sibships with prostate cancer. Am J Hum Genet 2000, 66(3):933-944. 209. Suarez BK, Lin J, Witte JS, Conti DV, Resnick MI, Klein EA, Burmester JK, Vaske DA, Banerjee TK, Catalona WJ: Replication linkage study for prostate cancer susceptibility genes. Prostate 2000, 45(2):106-114. 210. Sunwoo JB, Sun PC, Gupta VK, Schmidt AP, El-Mofty S, Scholnick SB: Localization of a putative tumor suppressor gene in the sub-telomeric region of chromosome 8p. Oncogene 1999, 18(16):2651-2655. 211. Suzuki H, Emi M, Komiya A, Fujiwara Y, Yatani R, Nakamura Y, Shimazaki J: Localization of a tumor suppressor gene associated with progression of human prostate cancer within a 1.2 Mb region of 8p22-p21.3. Genes Chromosomes Cancer 1995, 13(3):168-174. 212. Suzuki H, Komiya A, Emi M, Kuramochi H, Shiraishi T, Yatani R, Shimazaki J: Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers. Genes Chromosomes Cancer 1996, 17(4):225-233. 213. Takahashi S, Alcaraz A, Brown JA, Borell TJ, Herath JF, Bergstralh EJ, Lieber MM, Jenkins RB: Aneusomies of chromosomes 8 and Y detected by fluorescence in situ hybridization are prognostic markers for pathological stage C (pt3N0M0) prostate carcinoma. Clin Cancer Res 1996, 2(1):137-145. 214. Takahashi S, Qian J, Brown JA, Alcaraz A, Bostwick DG, Lieber MM, Jenkins RB: Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. Cancer Res 1994, 54(13):3574-3579. 215. Takahashi S, Shan AL, Ritland SR, Delacey KA, Bostwick DG, Lieber MM, Thibodeau SN, Jenkins RB: Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res 1995, 55(18):4114-4119. 216. Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, Dayananth P et al: A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 2001, 27(2):172-180. 217. Teixeira MR, Waehre H, Lothe RA, Stenwig AE, Pandis N, Giercksky KE, Heim S: High frequency of clonal chromosome abnormalities in prostatic neoplasms sampled by prostatectomy or ultrasound-guided needle biopsy. Genes Chromosomes Cancer 2000, 28(2):211-219. 218. Trapman J, Sleddens HF, van der Weiden MM, Dinjens WN, Konig JJ, Schroder FH, Faber PW, Bosman FT: Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. Cancer Res 1994, 54(23):6061-6064. 219. Tricoli JV: Y chromosome enumeration in touch preparations from 42 prostate tumors by interphase fluorescence in situ hybridization analysis. Cancer Genet Cytogenet 1999, 111(1):1-6. 220. Trybus TM, Burgess AC, Wojno KJ, Glover TW, Macoska JA: Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer. Cancer Res 1996, 56(10):2263-2267. 221. Uchida T, Wang C, Sato T, Gao J, Takashima R, Irie A, Ohori M, Koshiba K: BRCA1 gene mutation and loss of heterozygosity on chromosome 17q21 in primary prostate cancer. Int J Cancer 1999, 84(1):19-23. 222. Ueda T, Emi M, Suzuki H, Komiya A, Akakura K, Ichikawa T, Watanabe M, Shiraishi T, Masai M, Igarashi T et al: Identification of a I-cM region of common deletion on 13q14 associated with human prostate cancer. Genes Chromosomes Cancer 1999, 24(3):183-190. 223. Ueda T, Komiya A, Emi M, Suzuki H, Shiraishi T, Yatani R, Masai M, Yasuda K, Ito H: Allelic losses on 18q21 are associated with progression and metastasis in human prostate cancer. Genes Chromosomes Cancer 1997, 20(2):140-147. 224. Valeri A, Drelon E, Paiss T, Vogel W, de Petriconi R, Hautmann R, Fournier G, Mangin P, Berthon P, Cussenot O: [Genetic analysis of familial prostatic cancer: localization of a gene predisposing to prostatic cancer (PCaP) on chromosome 1q 42.2-43]. Prog Urol 1999, 9(4):680-688. 225. Van Alewijk DC, Van der Weiden MM, Eussen BJ, Van Den Andel-Thijssen LD, Ehren-van Eekelen CC, Konig JJ, van Steenbrugge GJ, Dinjens WN, Trapman J: Identification of a homozygous deletion at 8p12-21 in a human prostate cancer xenograft. Genes Chromosomes Cancer 1999, 24(2):119-126. 226. Van Dekken H, Alers J: Loss of chromosome Y in prostatic cancer cells but not in stromal tissue. Cancer Genet Cytogenet 1993, 66(2):131-132. 227. Van Dekken H, Krijtenburg PJ, Alers JC: DNA in situ hybridization (interphase cytogenetics) versus comparative genomic hybridization (CGH) in human cancer: detection of numerical and structural chromosome aberrations. Acta Histochem 2000, 102(1):85-94. 228. Van Den Berg C, Guan XY, Von Hoff D, Jenkins R, Bittner, Griffin C, Kallioniemi O, Visakorpi, McGill, Herath J et al: DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications. Clin Cancer Res 1995, 1(1):11-18. 229. van der Poel HG, Mulders PF, Aalders TW, Oosterhof GO, Debruyne FM, Schalken JA: Karyometric analysis of intra-tumour heterogeneity in prostate adenocarcinoma. Anal Cell Pathol 1994, 7(2):153-170. 230. Virgin JB, Hurley PM, Nahhas FA, Bebchuk KG, Mohamed AN, Sakr WA, Bright RK, Cher ML: Isochromosome 8q formation is associated with 8p loss of heterozygosity in a prostate cancer cell line. Prostate 1999, 41(1):49-57. 231. Visakorpi T, Hyytinen E, Kallioniemi A, Isola J, Kallioniemi OP: Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization. Am J Pathol 1994, 145(3):624-630. 232. Visakorpi T, Kallioniemi AH, Syvanen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP: Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995, 55(2):342- 347. 233. Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Strup SE, Duray PH, Liotta LA, Emmert-Buck MR, Linehan WM: Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res 1996, 56(10):2411-2416. 234. Wake N, Isaacs J, Sandberg AA: Chromosomal changes associated with progression of the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res 1982, 42(10):4131-4142. 235. Webb HD, Hawkins AL, Griffin CA: Cytogenetic abnormalities are frequent in uncultured prostate cancer cells. Cancer Genet Cytogenet 1996, 88(2):126-132. 236. Whittemore AS, Lin IG, Oakley-Girvan I, Gallagher RP, Halpern J, Kolonel LN, Wu AH, Hsieh CL: No evidence of linkage for chromosome 1q42.2-43 in prostate cancer. Am J Hum Genet 1999, 65(1):254-256. 237. Wick W, Petersen I, Schmutzler RK, Wolfarth B, Lenartz D, Bierhoff E, Hummerich J, Muller DJ, Stangl AP, Schramm J et al: Evidence for a novel tumor suppressor gene on chromosome 15 associated with progression to a metastatic stage in breast cancer. Oncogene 1996, 12(5):973-978. 238. Williams BJ, Jones E, Brothman AR: Homologous centromere association of chromosomes 9 and 17 in prostate cancer. Cancer Genet Cytogenet 1995, 85(2):143-151. 239. Wu SQ, Hafez GR, Zhang J, Newton M, Chen A, Lange J, Wilding G: Identification of the prostate cancer micro-foci with chromosome 8p deletion at the tumor interface area by histopathological-FISH parallel examination. Int J Oncol 2001, 19(6):1143-1147. 240. Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, Ewing C, Wilkens E, Bujnovszky P, Bova GS et al: Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 1998, 20(2):175-179. 241. Xu J, Zheng SL, Chang B, Smith JR, Carpten JD, Stine OC, Isaacs SD, Wiley KE, Henning L, Ewing C et al: Linkage of prostate cancer susceptibility loci to chromosome 1. Hum Genet 2001, 108(4):335-345. 242. Xu J, Zheng SL, Hawkins GA, Faith DA, Kelly B, Isaacs SD, Wiley KE, Chang B, Ewing CM, Bujnovszky P et al: Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8p22-23. Am J Hum Genet 2001, 69(2):341-350. 243. Yaremko ML, Recant WM, Westbrook CA: Loss of heterozygosity from the short arm of chromosome 8 is an early event in breast cancers. Genes Chromosomes Cancer 1995, 13(3):186-191. 244. Yin Z, Babaian RJ, Troncoso P, Strom SS, Spitz MR, Caudell JJ, Stein JD, Kagan J: Limiting the location of putative human prostate cancer tumor suppressor genes on chromosome 18q. Oncogene 2001, 20(18):2273-2280. 245. Yin Z, Spitz MR, Babaian RJ, Strom SS, Troncoso P, Kagan J: Limiting the location of a putative human prostate cancer tumor suppressor gene at chromosome 13q14.3. Oncogene 1999, 18(52):7576-7583. 246. Zenklusen JC, Thompson JC, Troncoso P, Kagan J, Conti CJ: Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1. Cancer Res 1994, 54(24):6370-6373. 247. Zheng SL, Xu J, Isaacs SD, Wiley K, Chang B, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB: Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families. Hum Genet 2001, 108(5):430-435. 248. Zitzelsberger H, Engert D, Walch A, Kulka U, Aubele M, Hofler H, Bauchinger M, Werner M: Chromosomal changes during development and progression of prostate adenocarcinomas. Br J Cancer 2001, 84(2):202-208. 249. Zitzelsberger H, Szucs S, Robens E, Weier HU, Hofler H, Bauchinger M: Combined cytogenetic and molecular genetic analyses of fifty-nine untreated human prostate carcinomas. Cancer Genet Cytogenet 1996, 90(1):37-44. 250. Zitzelsberger H, Szucs S, Weier HU, Lehmann L, Braselmann H, Enders S, Schilling A, Breul J, Hofler H, Bauchinger M: Numerical abnormalities of chromosome 7 in human prostate cancer detected by fluorescence in situ hybridization (FISH) on paraffin- embedded tissue sections with centromere- specific DNA probes. J Pathol 1994, 172(4):325-335.